Bao Zhong Zhang
Directeur Général chez Kunming Biomedical International Ltd.
Profil
Bao Zhong Zhang is currently the Chief Executive Officer at Kunming Biomedical International Ltd.
Prior to this, he worked as a Principal at Metabasis Therapeutics, Inc. and as Vice President & Head-Invivo Pharmacology at HD Biosciences Co., Ltd.
Zhang holds a doctorate degree from The University of Sydney (1996) and Dalian Medical University (1987).
Postes actifs de Bao Zhong Zhang
| Sociétés | Poste | Début |
|---|---|---|
Kunming Biomedical International Ltd.
 Kunming Biomedical International Ltd. BiotechnologyHealth Technology Kunming Biomedical International Ltd. specializes in non human primate disease models. The firm expertise in developing and running specialized primate animal models to test drug candidates and medical devices for its pharmacological effects and biocompatible repairs. It specializes in vivo pharmacology, clinical chemistry and bio analytics, drug metabolism and pharmacokinetics, non-GLP toxicology and safety pharmacology, and histology and pathology. The company was founded in 2006 and is headquartered in Kunming, China. | Directeur Général | - |
Anciens postes connus de Bao Zhong Zhang
| Sociétés | Poste | Fin |
|---|---|---|
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | - |
HD Biosciences Co., Ltd.
 HD Biosciences Co., Ltd. Medical/Nursing ServicesHealth Services HD Biosciences Co., Ltd. operates as a biotech company. It specializes in drug discovery contract research. The company offers comprehensive technology platforms and expertise services around hit to lead and lead optimization in preclinical drug discovery and development, which includes biology assays and assay development, compound profiling, high throughput screening, DMPK, in vivo pharmacology, drug efficacy and safety, as well as natural product based lead compound discovery. The company was founded in October 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | - |
Formation de Bao Zhong Zhang
| Dalian Medical University | Doctorate Degree |
| The University of Sydney | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
HD Biosciences Co., Ltd.
HD Biosciences Co., Ltd. Medical/Nursing ServicesHealth Services HD Biosciences Co., Ltd. operates as a biotech company. It specializes in drug discovery contract research. The company offers comprehensive technology platforms and expertise services around hit to lead and lead optimization in preclinical drug discovery and development, which includes biology assays and assay development, compound profiling, high throughput screening, DMPK, in vivo pharmacology, drug efficacy and safety, as well as natural product based lead compound discovery. The company was founded in October 2002 and is headquartered in Shanghai, China. | Health Services |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Health Technology |
Kunming Biomedical International Ltd.
Kunming Biomedical International Ltd. BiotechnologyHealth Technology Kunming Biomedical International Ltd. specializes in non human primate disease models. The firm expertise in developing and running specialized primate animal models to test drug candidates and medical devices for its pharmacological effects and biocompatible repairs. It specializes in vivo pharmacology, clinical chemistry and bio analytics, drug metabolism and pharmacokinetics, non-GLP toxicology and safety pharmacology, and histology and pathology. The company was founded in 2006 and is headquartered in Kunming, China. | Health Technology |
